SRSF2 Antibody

What are the most effective applications for SRSF2 antibodies in molecular biology research?

SRSF2 antibodies demonstrate versatility across multiple experimental applications. Based on comprehensive validation studies, these antibodies perform optimally in:

• Western Blotting (WB): Highly effective for detecting native and denatured SRSF2 protein (~25.5 kDa)

• Immunohistochemistry (IHC): Both paraffin-embedded and frozen section analysis

• Immunocytochemistry (ICC): Cellular localization shows predominantly nuclear distribution

• Immunoprecipitation (IP): Effective for protein-protein interaction studies

Research shows that antibody selection should be guided by the specific experimental application. For detecting SRSF2's nuclear localization, ICC applications demonstrate high sensitivity, while WB provides more quantitative assessment of expression levels .

How do I select the appropriate SRSF2 antibody for detecting specific protein domains?

Selection should be guided by the protein domain under investigation:

For research focusing on SRSF2 mutations in the P95 hotspot region, antibodies targeting the central domain (AA 76-105) show optimal specificity. Studies demonstrate that antibodies recognizing the RRM domain are particularly valuable for investigating SRSF2's RNA binding properties in acetylation studies .

What controls should be included when validating SRSF2 antibodies?

Proper validation requires these essential controls:

• Positive controls: HeLa cells express high levels of SRSF2 and serve as excellent positive controls for antibody validation .

• Knockdown controls: SRSF2 knockdown using shRNAs (like sh-SRSF2#1 and sh-SRSF2#2) provides specificity verification .

• Overexpression controls: Cells transfected with HA-tagged or Flag-tagged SRSF2 constructs help confirm antibody specificity .

• Cross-reactivity assessment: Test antibodies on lysates from multiple species when cross-species reactivity is claimed.

Research indicates that dual validation using both knockdown and overexpression approaches provides the most reliable antibody characterization. When studying post-translational modifications, specific controls like the acetylation-deficient SRSF2(K52R) mutant can verify antibody specificity for modified forms .

How can SRSF2 antibodies be employed to investigate post-translational modifications affecting splicing function?

Advanced investigation of SRSF2 post-translational modifications requires:

• Acetylation studies: Use anti-acetyl-lysine antibodies for co-immunoprecipitation with SRSF2 antibodies to detect acetylated forms. Research has identified K52 as a critical acetylation site affecting SRSF2 stability .

• Phosphorylation analysis: Sequential immunoprecipitation using phospho-specific antibodies followed by SRSF2 antibodies can reveal phosphorylation states that regulate SRSF2 function.

• Modification-specific antibodies: Custom antibodies like anti-Ac-K52 SRSF2 provide direct detection of specific modifications. Validation protocols should include:

  • Treatment with HDAC6 inhibitors to increase acetylated SRSF2

  • Comparison with SRSF2(K52R) mutant cells as negative controls

  • Western blotting verification following IP experiments

Research indicates that acetylation by Tip60 at K52 promotes proteasomal degradation of SRSF2, while deacetylation by HDAC6 increases stability. These modifications directly impact SRSF2's half-life and function in splicing regulation .

What are the optimal methods for investigating SRSF2 mutant proteins using antibodies?

Investigation of SRSF2 mutations, particularly the clinically significant P95H/L/R variants, requires specialized approaches:

• Generation of isogenic cell models: Using CRISPR-Cas9 system to create heterozygous P95H/+ models that maintain one wild-type allele, as homozygous mutations may be lethal .

• Antibody-based mutation verification:

  • Western blot comparison between wild-type and mutant cells

  • Combined IP/MS approaches to verify mutant protein expression

  • RNA-immunoprecipitation to assess altered RNA binding specificity

• Functional assessment protocols:

  • In vitro splicing assays using IgM pre-mRNA to assess SRSF2 function

  • Immunoprecipitation of spliced products to evaluate differential binding

Research demonstrates that mutant SRSF2 proteins maintain splicing activity but show altered binding preferences for exonic splicing enhancers. In vitro studies reveal that P95H/L/R mutants can precipitate both pre-mRNA and mRNA more efficiently than wild-type SRSF2, indicating altered rather than abolished function .

How can chromatin immunoprecipitation using SRSF2 antibodies inform splicing regulation mechanisms?

Advanced chromatin immunoprecipitation (ChIP) protocols using SRSF2 antibodies enable investigation of co-transcriptional splicing mechanisms:

• Sequential ChIP-seq methodology:

  • Formaldehyde crosslinking of chromatin

  • Immunoprecipitation with validated SRSF2 antibodies

  • Size selection for chromatin fragments of 200-300bp

  • Library preparation and next-generation sequencing

• Analysis of SRSF2 association with nascent transcripts:

  • RNA-ChIP approaches to capture SRSF2-nascent RNA interactions

  • iCLIP (individual-nucleotide resolution UV crosslinking and immunoprecipitation) using SRSF2 antibodies

• Splicing dynamics visualization:

  • ChIP-qPCR targeting intron-exon boundaries

  • Integration with RNA-seq data to correlate chromatin association with splicing outcomes

Research indicates that SRSF2 binding to pre-mRNAs is context-dependent, with binding to constitutive exons promoting inclusion of nearby alternative exons (e.g., SLMAP exon 24), while binding to other regions can promote exclusion (e.g., CETN3 exon 5) .

How can SRSF2 antibodies be employed to study myeloid malignancies with SRSF2 mutations?

SRSF2 antibodies play a critical role in hematological malignancy research through:

• Detection of mutation-specific splicing patterns:

  • Immunoprecipitation of SRSF2-bound transcripts followed by RNA-seq

  • Validation of aberrant exon usage in isogenic SRSF2 mutant models

  • Comparison with primary AML samples harboring P95 mutations

• Therapeutic target identification methodologies:

  • Antibody-based screening for SRSF2 mutant-selective compounds

  • IP-MS approaches to identify altered protein interactions in mutant cells

  • Validation of compounds like RKI-1447 in xenograft models using SRSF2 antibodies

• Monitoring nuclear morphology changes:

  • Immunofluorescence with SRSF2 antibodies to detect nuclear deformation

  • Co-staining with microtubule markers to assess cytoskeletal reorganization

Research has revealed that RKI-1447, identified through high-throughput drug screening, selectively targets SRSF2 mutant cells by inducing mitotic catastrophe through severe nuclear deformation, offering a potential therapeutic approach for myeloid malignancies carrying SRSF2 mutations .

What are the methodological considerations for using SRSF2 antibodies in colorectal cancer research?

While SRSF2 mutations are rare in colorectal cancer (CRC), SRSF2 expression changes remain significant:

• Expression analysis protocol:

  • IHC staining of CRC tumor tissues versus adjacent normal tissues

  • Quantitative assessment using tissue microarrays

  • Correlation with clinicopathological features

• Functional knockdown studies:

  • shRNA-mediated SRSF2 depletion in CRC cell lines

  • Assessment of proliferation using EdU incorporation

  • Cell cycle analysis via flow cytometry

• Splicing target identification:

  • RNA-seq following SRSF2 knockdown

  • RT-PCR validation of alternative splicing events

  • CLIP analysis to identify direct SRSF2 binding sites

Research demonstrates that SRSF2 is significantly upregulated in CRC tissues compared to normal colorectal tissues. Knockdown of SRSF2 inhibits CRC cell proliferation by arresting cells in G1 phase, suggesting SRSF2's oncogenic role through splicing regulation of cell cycle-related genes like SLMAP and CETN3 .

How can SRSF2 antibodies be utilized to investigate mitochondrial dysfunction in SRSF2-mutant leukemias?

Advanced methodologies for studying SRSF2-associated mitochondrial pathology include:

• Mitophagy assessment protocol:

  • Co-immunofluorescence of SRSF2 with mitochondrial markers (TOMM20)

  • Analysis of mitophagy pathway components (PINK1, PARKIN)

  • Quantification of mitochondrial-lysosomal colocalization (TOMM20/LAMP1)

• Mitochondrial function analysis:

  • Seahorse assays to measure oxygen consumption rate

  • Mitochondrial membrane potential assessment

  • ROS production measurement

• Mitophagy marker screening:

  • Quantitative PCR panel for mitophagy genes (PINK1, OPTN, ULK1)

  • Western blotting validation with specific antibodies

  • Correlation with SRSF2 mutation status

Research reveals that SRSF2 P95H mutation activates a mitochondrial surveillance mechanism, with significantly increased expression of mitophagy markers and enhanced mitochondrial-lysosomal colocalization, suggesting a novel therapeutic vulnerability in SRSF2-mutant leukemias .

What are the most common issues with SRSF2 antibody applications and how can they be resolved?

Research suggests that acetylation and phosphorylation of SRSF2 can significantly affect its molecular weight and antibody recognition. Including both acetylation inhibitors (like TSA) and phosphatase inhibitors in lysis buffers improves detection consistency .

How can SRSF2 antibody-based assays be optimized for detecting low abundance splice variants?

Detection of low abundance SRSF2-regulated splice variants requires specialized optimization:

• Enhanced IP-RT-PCR protocol:

  • RNA-immunoprecipitation using SRSF2 antibodies

  • DNase treatment of precipitated material

  • cDNA synthesis with random hexamers

  • Nested PCR targeting specific splice junctions

  • Analysis using high-sensitivity detection systems

• Splice junction-specific antibody development:

  • Generation of antibodies recognizing novel exon-exon junctions

  • Validation using synthetic peptides spanning junction sequences

  • Pre-absorption controls with competing peptides

• Digital PCR quantification:

  • Absolute quantification of rare splice variants

  • Droplet digital PCR following SRSF2 knockdown/overexpression

  • Comparison with RNA-seq PSI (Percent Spliced In) values

Research demonstrates high correlation between RT-PCR experimental validation of SRSF2-dependent alternative splicing events and RNA-seq analysis (ΔPSI values), confirming the validity of these approaches for splice variant detection .

What specialized protocols exist for investigating SRSF2 antibody epitope accessibility in different cellular compartments?

Advanced protocols for assessing SRSF2 epitope accessibility include:

• Nuclear extraction optimization:

  • Differential extraction using increasing salt concentrations

  • Analysis of SRSF2 distribution between soluble nuclear fraction and chromatin-bound fraction

  • Comparison of antibody reactivity across fractions

• In situ epitope accessibility assessment:

  • Titration of detergent concentrations during fixation

  • Comparison of methanol versus paraformaldehyde fixation

  • Antigen retrieval optimization for formalin-fixed tissues

• 3D imaging of nuclear SRSF2 distribution:

  • Super-resolution microscopy techniques

  • Z-stack image acquisition and 3D reconstruction

  • Co-staining with nuclear envelope markers

Research indicates that SRSF2 mutations can induce deep nuclear indentation and segmentation driven by microtubule-rich cytoplasmic intrusions. These structural changes may affect epitope accessibility and require specialized fixation and imaging protocols for accurate detection .

How can single-cell technologies be integrated with SRSF2 antibody-based approaches?

Emerging methodologies combining single-cell analysis with SRSF2 antibody applications include:

• Single-cell CyTOF with SRSF2 antibodies:

  • Metal-conjugated SRSF2 antibodies for mass cytometry

  • Multi-parameter analysis of SRSF2 expression with cell surface markers

  • Identification of rare cell populations with altered SRSF2 expression

• Single-cell RNA-seq with SRSF2 protein detection:

  • CITE-seq approaches combining transcriptomics with protein quantification

  • Correlation of SRSF2 protein levels with splicing patterns at single-cell resolution

  • Trajectory analysis of cells with SRSF2 mutations

• Spatial transcriptomics with SRSF2 IF:

  • In situ sequencing combined with SRSF2 immunofluorescence

  • Spatial mapping of splicing events in tissue sections

  • Correlation with disease progression in hematological malignancies

These approaches will enable unprecedented resolution in understanding SRSF2 function and dysfunction in heterogeneous cell populations, particularly in the context of clonal hematopoiesis where SRSF2 mutations define high-risk individuals for AML progression .

What new therapeutic approaches targeting SRSF2 mutations can be monitored using antibody-based assays?

Emerging therapeutic strategies and their monitoring methodologies include:

• ROCK inhibitor therapy assessment:

  • Quantification of nuclear morphology changes using SRSF2 antibodies

  • Monitoring of mitotic catastrophe following RKI-1447 treatment

  • Assessment of cytoskeletal reorganization effects

• Splicing modulator efficacy monitoring:

  • SRSF2 antibody-based RNA-IP to track splicing pattern normalization

  • Quantification of aberrant exon usage as pharmacodynamic biomarker

  • Correlation with clinical response in patient samples

• Combination therapy approaches:

  • Analysis of SRSF2/JAK2 mutation synergy in treatment response

  • Assessment of TGF-β, S100A8, and S100A9 expression changes

  • Monitoring of hematopoietic stem/progenitor cell competitiveness

Research has identified RKI-1447 as a promising therapeutic agent for SRSF2-mutant leukemias, with evidence suggesting it exacerbates the nuclear deformation phenotype associated with SRSF2 mutations, preventing cells from completing mitosis .

How might antibody engineering improve detection and functional analysis of SRSF2 and its mutations?

Advanced antibody engineering approaches show promise for enhanced SRSF2 research:

• Mutation-specific antibody development:

  • Generation of antibodies specifically recognizing P95H/L/R mutations

  • Phage display selection against mutant versus wild-type peptides

  • Validation in isogenic cell lines and patient samples

• Proximity labeling applications:

  • SRSF2-APEX2 fusion proteins for spatial proteomics

  • BioID approaches to identify novel SRSF2 interactors

  • TurboID systems for rapid labeling of transient interactions

• Intracellular antibody fragments (intrabodies):

  • Development of single-chain variable fragments targeting SRSF2

  • Expression in living cells to track SRSF2 dynamics

  • Potential therapeutic applications through mutant SRSF2 targeting

These approaches hold potential for more precise detection of SRSF2 mutations in patient samples and could facilitate development of targeted therapies for myeloid malignancies harboring SRSF2 mutations, which represent high-risk leukemogenic precursors that might be preventively targeted .